|
Networking & Consortia
Networking Pre Event
CPhI India 2009 to introduce BioPh trail: Bio-Solutions for Pharma
After the successful introduction in 2007 of ICSE trail at
CPhI India, UBM India is now proud to introduce BioPh: Bio-Solutions for Pharma.
A survey of visitors of the 2007 event showed that 85 percent of visitors stated
that they would be interested in meeting more exhibitors that offer biotechnology
products and natural extracts. The in-licensing of new technologies from biopharmaceutical
companies has become a trusted alternative method of bringing drugs to market.
Today nearly 50 percent of all manufactured drugs are derived from biotech.
All companies and organisations dealing with the research and development of
new treatment methods made through biotechnological processes or which are derived
from or use live organisms will benefit from exhibiting at BioPh. Some of the
companies participating in this year's event include Vasta Biotech, Titan Biotech,
Hi Tech Biosciences, Health Biotech, Advanced Enzyme Technologies, United Biotech,
S.M. Biomed Sdn. Bhd, Bio Mittledeutschland and many more are expected to confirm
their participation soon. Hosting such an event alongside, CPhI ICSE and PMEC
offers unequalled networking and commercial opportunities, creating a perfect
synergy in the world of drug research and manufacturing.
Indian pharmaceutical companies are now making their initial presence felt in
the biotech arena. India has the potential to become a major player in biotech
and cultivating the domestic biotech market is one major focus of the Indian
government. The importance of the biotech market in India and its prospective
growth can be seen from the steps taken by the Indian government to further
develop research and entrepreneurship initiatives in the country. The Department
of Biotechnology and the various Centres of Excellence provide the backbone
of furthering research activities and laying the foundation for generating knowledge
and trained manpower to assist entrepreneurship programs and the biotech private
industry in India. Several pharma companies have already jumped into the Indian
biotech market to take advantage of the opportunities in this new and exciting
field. India currently has a number of biotech parks and the construction of
more such parks is expected to significantly increase research capacity. The
pharma industry has been boosted by news that many more biotech parks are to
be set up and financial actions are being implemented to help small businesses.
India's long-established destination as a preferred manufacturing location for
multinational manufacturers,is quickly spreading into other areas of outsourcing
activities and she now also has a small group of venture funded innovative biotech
companies.
The global pharma markets are undergoing a sea change .The forecast is that
established pharma markets of Western Europe and the US are expected to slow
down. Markets in the US and Europe are in a stage of consolidation and cost
reduction measures in healthcare will limit growth opportunities in the established
large markets. Soaring costs of R&D and administration are persuading drug
manufacturers to move discovery research, clinical trials and administrative
center activities to the subcontinent to capitalise on India's high levels of
scientific expertise and associated cost efficiency.
As a result, current acquisition activities in the region aim to either establish
an attractive product pipeline or reduce structural costs by benefiting from
economies of scale.
What is happening to the established global markets need not necessarily overshadow
the growing interest from Indian pharma companies in acquiring companies in
Europe and the US to accelerate their entry into the world's largest markets.
Many international financial markets are looking towards speeding up the realisation
of the return on investment. How to access and leverage such opportunities in
and out of India is clearly going to be important in further determining the
successes of the Indian pharma industry in the global markets.
Already many Indian domestic players are starting to build global businesses
by investing in M&A in Europe and the US, and also developing new products.
For any firm in the pharma, biotech and life science investment industry, the
question will be how to capture the business opportunities emerging in an environment
of rapid growth. Can we leverage the capabilities of the existing domestic biopharma
industry in order to find solutions for some of the most challenging issues
of health care and disease treatment in the second most populous country in
the world?
For more information on exhibiting at BioPh : bio solutions
for pharma, please contact Chaitali Patil on 91 22 66122600 or email at chaitalip@ubmindia.com
|
